West Pharmaceutical Services, Inc. (WST)
| Market Cap | 26.51B +40.9% |
| Revenue (ttm) | 3.33B +12.4% |
| Net Income | 564.90M +15.8% |
| EPS | 7.81 +16.8% |
| Shares Out | 70.38M |
| PE Ratio | 48.23 |
| Forward PE | 40.54 |
| Dividend | $0.88 (0.23%) |
| Ex-Dividend Date | Jul 29, 2026 |
| Volume | 560,022 |
| Open | 375.51 |
| Previous Close | 375.65 |
| Day's Range | 370.80 - 377.78 |
| 52-Week Range | 223.83 - 386.00 |
| Beta | 1.14 |
| Analysts | Strong Buy |
| Price Target | 407.56 (+8.21%) |
| Est. Earnings | Oct 22, 2026 |
About WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhanc... [Read more]
Financial Performance
In 2025, WST's revenue was $3.07 billion, an increase of 6.25% compared to the previous year's $2.89 billion. Earnings were $493.70 million, an increase of 0.20%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for WST stock is "Strong Buy." The 12-month stock price target is $407.56, which is an increase of 8.21% from the latest price.
News
West Pharmaceutical upgraded to Overweight at Morgan Stanley on durable growth
As previously reported, Morgan Stanley analyst Kallum Titchmarsh upgraded West Pharmaceutical (WST) to Overweight from Equal Weight with a price target of $400, up from $365. West will benefit materia...
West Pharmaceutical upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh upgraded West Pharmaceutical (WST) to Overweight from Equal Weight with a price target of $400, up from $365.
West Pharmaceutical Services Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Q2 saw 13% revenue growth and raised full-year guidance, with HVP and GLP-1 segments leading performance. Regulatory upgrades, APAC expansion, and premium product mix are driving margin gains, while investments in capacity and automation support long-term growth.
West Pharmaceutical Services Transcript: Wells Fargo 21st Annual Healthcare Conference
Leadership transition is expected to accelerate growth initiatives and customer engagement. Q2 results beat expectations, prompting raised guidance and margin expansion, driven by HVP components, biologics, and GLP-1s. Investments focus on high-value solutions and capital efficiency.
West Pharmaceutical assumed with a Buy at UBS
UBS assumed coverage of West Pharmaceutical (WST) with a Buy rating and $415 price target West is an attractive growth and margin expansion story, driven by the continued strength of…
West to Participate in Upcoming Investor Conferences
EXTON, Pa., Aug. 26, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will prese...
West Pharmaceutical price target raised to $412 from $400 at Citi
Citi raised the firm’s price target on West Pharmaceutical (WST) to $412 from $400 and keeps a Buy rating on the shares.
West Pharmaceutical price target raised to $425 from $410 at Evercore ISI
Evercore ISI raised the firm’s price target on West Pharmaceutical (WST) to $425 from $410 and keeps an Outperform rating on the shares.
West Pharmaceutical price target raised to $410 from $400 at BofA
BofA raised the firm’s price target on West Pharmaceutical (WST) to $410 from $400 and keeps a Buy rating on the shares after what the firm calls “another beat and…
GLP-1 concerns around West Pharmaceutical feel overdone, says Evercore ISI
Evercore ISI reiterated an Outperform rating and $410 price target on West Pharmaceutical (WST) after the company reported quarterly results. The firm said the main questions it has received Thursday…
West Pharmaceutical Services Earnings Call Transcript: Q2 2026
Q2 2026 saw double-digit revenue and EPS growth, driven by strong HVP components and biologics demand, with robust performance across all geographies. Full-year guidance was raised, reflecting high teens growth in HVP components and continued margin expansion.
West Pharmaceutical Services Earnings release: Q2 2026
West Pharmaceutical Services released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
West Pharmaceutical Services Slides: Q2 2026
West Pharmaceutical Services has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
West Pharmaceutical Services Quarterly report: Q2 2026
West Pharmaceutical Services has published its Q2 2026 quarterly earnings report on July 23, 2026.
West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components
West Pharmaceutical Services raised its annual profit and revenue forecasts on Thursday as strong demand for components used in injectable drugs, including diabetes and obesity treatments, helped it...
West Reports Second-Quarter 2026 Results
Raising Full-Year Net Sales and EPS guidance EXTON, Pa., July 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutio...
West Declares Quarterly Dividend
EXTON, Pa., July 21, 2026 /PRNewswire/ -- On July 21, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug admini...
West Pharmaceutical price target raised to $410 from $365 at TD Cowen
TD Cowen raised the firm’s price target on West Pharmaceutical (WST) to $410 from $365 and keeps a Buy rating on the shares. The firm cites an improved earnings outlook…
West Pharmaceutical initiated with an Outperform at BNP Paribas
BNP Paribas initiated coverage of West Pharmaceutical (WST) with an Outperform rating and $447 price target
West Pharmaceutical price target raised to $365 from $325 at Morgan Stanley
Morgan Stanley raised the firm’s price target on West Pharmaceutical (WST) to $365 from $325 and keeps an Equal Weight rating on the shares. The firm is updating its model…
West to Host Second-Quarter 2026 Conference Call
EXTON, Pa., July 7, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will releas...
West Pharmaceutical price target raised to $410 from $390 at Evercore ISI
Evercore ISI analyst Daniel Markowitz raised the firm’s price target on West Pharmaceutical (WST) to $410 from $390 and keeps an Outperform rating on the shares. The firm’s Q2 preview…
West Pharmaceutical price target raised to $390 from $350 at KeyBanc
KeyBanc raised the firm’s price target on West Pharmaceutical (WST) to $390 from $350 and keeps an Overweight rating on the shares. The firm cites increased confidence in West Pharmaceutical…
West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
EXTON, Pa., July 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the company complet...
Barclays upgrades West Pharmaceutical on ‘material’ upside to estimates
Barclays analyst Luke Sergott upgraded West Pharmaceutical (WST) to Overweight from Equal Weight with a price target of $400, up from $310. The firm says it overestimated the risk from…